Skip to main content

amdizalisib

Generic: Amdizalisib

amdizalisib: 2 clinical trials tracked.

amdizalisib evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about amdizalisib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

NCT04849351Registry updated 2025-04-06·Phase 2
Completed

Primary endpoint: Overall response rate (ORR)

Interventionalopen178 enrolledStarted 2021-04Completion 2024-0250 sites · ChinaHutchison Medipharma Limited

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma

NCT03786926Registry updated 2025-06-26·Phase 1
Terminated

Primary endpoint: Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)

Interventionalopen53 targetStarted 2019-08Completion 2024-0627 sites · Finland, France, Italy, Poland…Hutchmed